Targeted Oncology1d
FDA Grants PYX-201 Fast Track Status in HNSCC
PYX-201 has gained FDA fast track designation in recurrent or metastatic head and neck squamous cell carcinoma.
FDA grants fast track status to Pyxis’ PYX-201
The US Food and Drug Administration (FDA) has granted fast track designation to Pyxis Oncology’s antibody-drug conjugate (ADC ...
manilatimes2d
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...
Pyxis Oncology granted Fast Track designation for PYX-201 monotherapy
Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...
Pyxis Oncology rises on FDA fast track tag for lead asset
Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...
Taiwan News24d
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 ...
Nasdaq24d
Pyxis Oncology Initiates New Combination Trial For PYX-201 And Expands Monotherapy Cohorts
(RTTNews) - Pyxis Oncology, Inc. (PYXS), a clinical-stage company developing innovative cancer therapies, on Tuesday announced the initiation of a Phase 1/2 combination trial for PYX-201 ...